ALCAM/CD166, His, Cynomolgus
ALCAM/CD166, His, Cynomolgus

Immobilized ALCAM/CD166, His, Cynomolgus, His Tag at 2 μg /ml (100 μl /well) on the plate. Dose response curve for Anti-ALCAM Antibody, hFc Tag with the EC50 of 0.22 μg /ml determined by ELISA.

ALCAM/CD166, His, Cynomolgus

The purity of ALCAM/CD166, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

ALCAM/CD166, His, Cynomolgus

ALCAM/CD166, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

ALCAM/CD166, His, Cynomolgus

Brain metastasis (BM) in non-small-cell lung cancer (NSCLC) has a very poor prognosis. Recent studies have demonstrated the importance of cell adhesion molecules in tumor metastasis.Elevated levels of ALCAM expression promote BM formation in NSCLC through increased tumor cell dissemination and interaction with the brain endothelial cells. Therefore, ALCAM could be targeted to reduce the occurrence of BM.
Z04727
¥72,752.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
ALCAM/CD166 (Trp28-Lys527)
Accession # G7NZQ8		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 57.10 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 70-85 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • ALCAM/CD166, His, Cynomolgus
    • ALCAM/CD166, His, Cynomolgus

    Immobilized ALCAM/CD166, His, Cynomolgus, His Tag at 2 μg /ml (100 μl /well) on the plate. Dose response curve for Anti-ALCAM Antibody, hFc Tag with the EC50 of 0.22 μg /ml determined by ELISA.

  • ALCAM/CD166, His, Cynomolgus
    • ALCAM/CD166, His, Cynomolgus

    The purity of ALCAM/CD166, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

  • ALCAM/CD166, His, Cynomolgus
    • ALCAM/CD166, His, Cynomolgus

    ALCAM/CD166, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Brain metastasis (BM) in non-small-cell lung cancer (NSCLC) has a very poor prognosis. Recent studies have demonstrated the importance of cell adhesion molecules in tumor metastasis.Elevated levels of ALCAM expression promote BM formation in NSCLC through increased tumor cell dissemination and interaction with the brain endothelial cells. Therefore, ALCAM could be targeted to reduce the occurrence of BM.
Synonyms CD166; ALCAM; MEMD; CD6L; KG-CAM

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.